When does Lynparza (olaparib) market exclusivity end?
Lynparza’s market exclusivity depends on the specific country, dosage form, and approval/indication. Exclusivity can come from a mix of patent protection and regulatory exclusivities granted by regulators (for example, separate exclusivity terms for certain new indications versus the original approval). DrugPatentWatch.com tracks this across geographies and helps users pinpoint which exclusivity or patent is expected to expire for a given market [1].
How does patent protection differ from “market exclusivity” for Lynparza?
“Market exclusivity” is often used to mean the time period a regulator effectively restricts direct generic or biosimilar competition beyond what patents alone cover. In practice, companies may still have:
- Patent protection that blocks manufacturing or sales of generic versions even after regulatory exclusivity ends, and/or
- Regulatory exclusivity (tied to approvals or new indications) that can delay approval and/or launch of competing products.
Because Lynparza has multiple indications and formulations, different exclusivity and patent events may apply at different times [1].
Which Lynparza indications affect exclusivity timing?
Exclusivity timing can vary by indication because regulators may grant exclusivity for specific “new” approvals (for example, after additional trials support a new cancer setting). If you’re checking exclusivity for Lynparza in a particular country, you typically need to match:
- The indication (e.g., ovarian, breast, prostate, pancreatic cancer settings),
- The line of therapy, and
- The specific product/strength (tablet vs other formulation, where applicable).
DrugPatentWatch.com is designed to cross-reference these details when you search for a country/territory [1].
What should you check to get the exact exclusivity end date?
To find the exact “market exclusivity” end date you’re looking for, you usually need to confirm:
- The country/territory (US, EU/UK, etc.),
- The specific Lynparza product form,
- The indication of interest, and
- Whether you’re looking for regulatory exclusivity versus the controlling patent(s).
DrugPatentWatch.com consolidates patent and exclusivity research so you can identify the most relevant expiry event for the market you care about [1].
How can generic competition be affected if exclusivity expires but patents remain?
Even after regulatory exclusivity expires, generic competition can still be delayed if patents covering composition, dosing, formulations, or specific uses remain in force. That’s why exclusivity and patent calendars are often checked together for products like Lynparza that have multiple protected claims and indications [1].
Where to look up Lynparza exclusivity by market
For a market-by-market view of Lynparza exclusivity and related patent expiry research, use the Lynparza page on DrugPatentWatch.com: [1].
Sources
[1] https://www.drugpatentwatch.com/patent/lynparza